ArticleCurrent pharmaceutical design2026
Article in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHypertension is a major global health concern, and the exploration of natural compounds as potential antihypertensive agents has been a recent area of study. The ancient medicinal tree Terminalia arjuna is very potent for treating cardiovascular conditions. Its bark is rich in bioactive compounds, such as flavonoids, tannins, and triterpenoids, which exhibit cardioprotective properties.
methodsThis research focused on identifying and characterizing antihypertensive phytoconstituents of Terminalia arjuna through molecular docking, dynamic simulations, and DFT studies. We systematically screened bioactive compounds from the plant for their ability to interact with key targets (PDB:2X96), which are involved in the regulation of blood pressure using AutoDock Tools 1.5.7. The dynamic behavior of the complexes was evaluated using molecular dynamics (MD) simulation in the GROMACS package program (version 2022.2). DFT calculations were performed using DMol3 (Discovery Studio Client) to determine molecular electronic properties.
resultsWe identified Quercetin and Ellagic acid as promising ligands with strong binding affinities and significant pre-ADMET analysis database. Further, molecular dynamics simulations (500 ns) provided insights into the stability and binding modes of these selected compounds, highlighting their potential for long-term efficacy. DFT calculations were employed to evaluate the electronic properties, such as frontier molecular orbital analysis and electrostatic potential mapping, revealing the reactivity and interaction profiles of the compounds. The docking scores and MMGBSA binding free energy value of Ellagic acid with AnCE-RXPA380 complex target protein were found to be -9.5 and -17.94 kcal/mol, respectively, which is higher as compared to Captopril (--5.7 and --4.36 kcal/mol kJ/mol). DISCUSSION: Ellagic acid exhibits more conventional hydrogen binding efficiency at 2X96 receptor with GLN A:361, THR A:364, ASP A:360, LYS A:495, and GLN A:265, respectively, providing a scientific basis for its use in hypertension management Furthermore.
conclusionOur results suggest that Ellagic acid from Terminalia arjuna possesses significant antihypertensive potential due to the highest binding efficiency with 2X96 receptor. However, in vitro, and in vivo experimentation are needed to validate the antihypertensive potential of Ellagic acid in the future.
Indexed as
Identifiers
41764626What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.